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Abstract
Aims After decades of experience and strongly improved
technology, service time of pacemaker generators is ex-
pected to increase. To test this hypothesis, we conducted
a retrospective review of a large cohort of patients with
a pacemaker.
Methods We reviewed data collected between 1984 and
2006 in the first national Dutch pacemaker registry. This
registry covered 96% of all generators implanted. We anal-
ysed the time of and reason for explantation of pacemaker
generators. A 7-year follow-up interval after first implan-
tation and following replacements was used to analyse
changes over time.
Results During 22 years of data collection, nearly 97,000
first pacemaker generators were implanted. A total of
27,937 (22.4%) generators were explanted within a mean
of 6.3 (standard deviation 3.3) years. Reasons for approxi-
mately 60% of these explantations were ‘end of life’ of the
pacemaker generator or elective system change. Complica-
tions or failures such as infections and recalls accounted for
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approximately 20% of the explantations. For the remaining
20%, the reasons for explantation had not been registered.
Conclusion Despite progress in technology, a substantial
proportion of pacemaker generators is explanted before its
expected service time, with one in five generators being re-
placed due to technical failures, infections or other compli-
cations. Furthermore, the time interval between pacemaker
implantation and explantation due to normal ‘end of life’
(battery EOL) decreased. Infections continue to rank highly
as a cause for pacing system replacement, despite all current
preventive measures.
Keywords Pacemaker longevity · Pacemaker follow-up ·
Generator replacement · Pacemaker infection · Pacemaker
recall
Introduction
Chronic stimulation of the heart with pacemakers for brady-
cardia and other indications has been applied worldwide in
increasing numbers [1, 2]. In the Netherlands, 3236 first
pacemakers were implanted in 1984 (225 implants per mil-
lion inhabitants) [3], while 10,389 pacemakers were im-
planted in 2011 (468/million inhabitants) [4].
Pacing devices have become technically more sophis-
ticated to enable further options for sensing, pacing and
monitoring, as well as sustainability for simultaneous use
of other devices and techniques such as magnetic resonance
imaging. At the same time, the devices got substantially
smaller [5–7]. These developments required a more robust
design of the device, IT facilities, and increased lifespan of
the battery. The incremental need of remote monitoring to
support an intense technical follow-up to optimise the care
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of the individual pacemaker recipient also required techni-
cal innovations.
Because previous surveys showed a substantial compli-
cation rate [5, 6, 8, 9], we aimed to investigate trends in the
duration of service time or longevity of pacemaker gener-
ators after first implantation and re-implantation. For this
purpose, we studied the reasons for replacement of pace-
makers. We anticipated that growing experience, guidelines
and clustering of treatment facilities would increase service
time of the devices and complication rates would gradually
diminish over several decades.
Patients and methods
Setting
Data were retrieved from the Central Pacemaker Patients
Registration (CPPR) from the Netherlands Pacemaker Reg-
istry Foundation (CPPR-SPRN). The registry has been de-
scribed in detail elsewhere [3, 10]. In brief: in 1982, CPPR-
SPRN was established and the computerised registration be-
gan. Cardiologists and allied professionals were invited to
voluntarily register data of each patient, pacemaker gen-
erator and leads on the former European pacemaker card.
Data on symptoms, indication and diagnosis, brand of pace-
maker and leads, type, follow-up visits, explantation, hospi-
tal transfer and death were registered according to European
Registry Guidelines established in 1982 and later.
Monitoring and validation of data
Until 1989, data were registered centrally; a carbon copy of
the European pacemaker card had to be sent to the registry.
From 1989 onwards, a digitalised registration was used with
automatic communication between the central registration
computer and the local computer of the implanting centre.
During daily conversions into the database, multiple checks
were performed on missing data, conformation with already
stored information and plausibility [11]. Additionally, the
data were periodically returned to the clinics for correc-
tion purposes. In 1997, a validation process was performed
to obtain a better insight into the quality of the database.
When the central registry was compared with patient files of
participating hospitals and sales data from manufacturers,
95.7% of pacemaker generators could be retrieved [12].
Cohort and outcome definition
Patients admitted for implantation of the first pacemaker
between 01.01.1984 and 01.01.2006 were included in this
nationwide cohort study. A total of 452 implantations were
excluded because of inconsistencies in the registered data,
e. g. a new implantation was registered after the supposed
date of death of a patient, or the same pacemaker was regis-
tered more than once with different explantation dates. This
resulted in a cohort with 96,900 patients having a first pace-
maker implanted between January 1984 and January 2006,
followed by 27,937 explantations (of which 27,659 replace-
ment procedures) until January 2008. The years 2006 and
2007 were used for follow-up only. Additionally, for part
of the analyses, the cohort was subdivided into three strata
with 7 years of follow-up after each implantation, leaving
66,223 patients who received a first pacemaker between
January 1984 and January 2001.
Exposure
The primary interest was the number of pacemaker replace-
ments or explantations and the reasons for these interven-
tions. In this study ‘service time’ is defined as the time be-
tween pacemaker implantation and replacement or removal
of the generator.
Analysis
Analyses of explantations and replacements were per-
formed on:
1. the entire cohort of patients (n = 96,900) having first im-
plantations and re-implantations during the study period
irrespective of available duration of follow-up, and
2. three strata (n = 66,223 patients) to identify changes over
time.
Each implantation in these strata was followed for a max-
imum of 7 years or until explantation, whichever came first.
For this purpose, first implantations and re-implantations
during the years 1984–2000 could be used, while data from
2001–2007 were used for follow-up only. We chose a 7-year
follow-up period because the mean duration of follow-up
for explanted pacemaker generators falls within this time
interval, as also observed by Hauser et al. [13]. Further-
more, with 66,223 first implantations during 1984–2000,
two thirds of the cohort would remain available for analy-
sis. P-values were calculated with chi-square analysis and
independent samples t test.
Sensitivity analysis
To estimate the proportion of deaths that was (voluntarily)
registered in SPRN, we performed a sensitivity analysis
by looking up patients from the Rotterdam Study, a large
prospective cohort study on inhabitants of the Ommoord
area in Rotterdam [14], in the SPRN database. First, we
investigated on basis of gender and date of birth whether
a participant from the Rotterdam Study was registered in
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Table 1 Baseline characteristics of patients in the nationwide CPPR-SPRN database having a first pacemaker implanted (n = 96,900), the
Netherlands 1984–2007
1984–1990 1991–1995 1996–2000 2001–2005 2006–2007 Total study
period
Patientsa
Mean age at first implantation, years
(SD)
72.7 (13.0) 73.0 (13.0) 72.9 (13.2) 73.1 (12.9) NA 72.9 (13.0)
Female gender, n (%) 11,628
(48.7)
9419 (47.9) 10,569
(46.6)
14,045
(45.8)
NA 45,661 (47.1)
Deaths, n (% of patients that received
first pacemaker in this period)b
7245 (30.4) 6119 (31.1) 5849 (25.8)c 3721 (12.1)c NA 22,934 (23.7)
Follow-up duration (range), years 17–23 12–16 7–11 2–6 NA 2–23
Pacemaker generators
Implantations, n (% of totalb im-
planted pacemakers during study
period), of which:
24,952
(20.0)
23,451
(18.8)
29,789
(23.9)
41,569
(33.4)
4798 (3.9) 124,559
(100.0)
– First pacemaker 23,870
(95.7)
19,659
(83.8)c
22,694
(76.2)c
30,677
(73.8)c
NA 96,900 (77.8)
– First replacement 1004 (4.0) 3352 (14.3)c 5821 (19.5)c 8386 (20.2) 3571 (74.4) 22,134 (17.8)
– Second replacement 73 (0.3) 389 (1.7)c 1050 (3.5)c 1930 (4.6)c 908 (18.9) 4350 (3.5)
– Third or more replacement 5 (<0.1) 51 (0.2)c 224 (0.8)c 576 (1.4)c 319 (6.6) 1175 (0.9)
Explantation of pacemakers implanted
in this period, n (%), of which:
7238 (29.0) 8402 (35.8)c 9250 (31.1)c 3000 (7.2)c 47 (1.0) 27,937 (22.4)
– Explantation <7 years, n (%) 3233 (44.7) 4489 (53.4)c 5745 (62.1)c NA NA 16,514 (59.1)
– Explantation <5 years, n (%) 1692 (23.4) 1972 (23.5) 2455 (26.5)c NA NA 8586 (30.6)
– Explantation <3 years, n (%) 950 (13.1) 943 (11.2)c 1196 (12.9)c NA NA 4683 (16.8)
Without replacement/without immedi-
ate replacement, n (%)
41 (0.6) 33 (0.4) 66 (0.7) 181 (6.0)c 11 (23.4) 332 (1.2)
Mean duration of service time for
explanted pacemakers, years (SD)
7.7 (4.0) 6.8 (3.0)c 6.0 (2.4)c 2.9 (2.0)c 0.5 (0.5) 6.3 (3.3)
Median duration service time for ex-
planted pacemakers, years
7.5 6.8 6.4 2.8 0.3 6.4
For 2006–2007 we used data on replacements only
SD standard deviation, NA not available
aFor 75 patients, data on gender was missing. For 38 males and 22 females, data on age was missing
bData on number of deaths is incomplete
cSignificantly different compared to previous time interval (p  0.001), 2006–2007 not tested
SPRN. Subsequently, we validated each retrieval by using
the pacemaker implant date. The date of death is registered
for each participant of the Rotterdam Study.
Results
Between 01.01.1984 and 01.01.2006, 96,900 patients re-
ceived a first pacemaker. Approximately 53% of the patients
were men and the mean age at time of first implantation was
72.9 years (standard deviation [SD] 13.0). Baseline charac-
teristics are provided in Tab. 1.
Pacemaker generator replacements and removals
During the study period, 22,134 patients (22.8%) had at
least one pacemaker generator replacement or removal and
4350 patients (4.5%) had more than one. In total, 27,937
pacemaker generators were replaced or removed (22.4% of
total number of implants), including 332 pacemaker gen-
erators that were coded as a removal without replacement,
although it appeared that some of these patients did receive
a new pacemaker after several weeks to months (Tab. 1).
The mean duration of follow-up to pacemaker generator re-
placement or removal (service time) during the whole study
period was 6.3 (SD 3.3) years. Approximately 60% of the
explantations occurred within 7 years after implantation,
30.6% within 5 years and 16.8% within 3 years (Tab. 1).
Approximately 19% of the pacemaker generators were
replaced or removed following device failure or compli-
cations and in 20% the reason for explantation was not
available (Tab. 2). Analysis of pacing systems stratified for
the period in which a pacemaker was implanted and fol-
lowed for a maximum of 7 years shows that the percent-
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Table 2 Reasons for pacemaker generator replacements within 7 years of follow-up after implantation, stratified for implantation period, and for
the entire cohort irrespective of duration of follow-up in the nationwide CPPR-SPRN database, the Netherlands 1984–2007
Reason for explantation of pacemaker generators within 7 years of follow-up, stratified for implantation perioda
n (% of explanted pacemakers)
All pacemakers
explanted during
study periodb
1984–1990 1991–1995 1996–2000 1984–2007
Device failure
(sensing, programming, output, rate, connector)
126 (3.9) 151 (3.4) 105 (1.8)c 509 (1.8)
Recall 32 (1.0) 174 (3.9)c 270 (4.7) 583 (2.1)
Infection 149 (4.6) 176 (3.9) 248 (4.3) 884 (3.2)
Other complication
(mechanical protrusion, erosion, wound pain)
31 (1.0) 31 (0.7) 39 (0.7) 153 (0.5)
Elective for system change 319 (9.9) 450 (10.0) 554 (9.6) 2775 (9.9)
System change – Haemodynamic reasons 90 (2.8) 261 (5.8)c 398 (6.9) 1513 (5.4)
System change – Electrode problem 182 (5.6) 325 (7.2) 178 (3.1)c 1003 (3.6)
System change – other reasons 37 (1.1) 53 (1.2) 61 (1.1) 214 (0.8)
Normal ‘end of life’, of which: 908 (28.1) 1800 (40.1)c 2678 (46.6)c 14,077 (50.4)
– <7 years, n (% of all explantations <7 yearsd) 908 (28.1) 1800 (40.1)c 2678 (46.6)c 6349 (38.4)
– <5 years, n (% of all explantations <5 yearsd) 202 (11.9) 393 (19.9)c 587 (23.9) 1759 (20.5)
– <3 years, n (% of all explantations <3 yearsd) 29 (3.1) 48 (5.1) 87 (7.3) 307 (6.6)
Premature ‘end of life’ 77 (2.4) 140 (3.1) 126 (2.2) 520 (1.9)
Reason uncoded, unknown or unspecified 1282 (39.6) 928 (20.7)c 1088 (18.9) 5706 (20.4)
Total 3233 (100.0) 4489 (100.0) 5745 (100.0) 27,937 (100.0)
aFor each stratum, the duration of follow-up was maximised at 7 years. Hence, the years 2001–2007 were used for follow-up only. Consequently,
numbers of the first three columns do not add up to the numbers in the fourth column
bRegardless duration of follow-up
cSignificantly different compared to previous time interval (p  0.001)
dSee Tab. 1
age of explantations within 7 years due to infection lies
between 4.0–4.5% for pacemaker generators and did not
significantly change over time. The percentage of recalled
pacemaker generators within 7 years of implantation in-
creased during the study period, whereas the percentage of
device failures significantly decreased towards the end of
the study period from 3.9 to 1.8% of the pacemaker gener-
ator replacements (p  0.001; Tab. 2).
A total of 50.4% of pacemaker generators were explanted
because of normal ‘end of life’ of the generator (Tab. 2).
For these generators, the service time varied widely. When
compared to the number of explantations within different
periods of follow-up, 38.4% of the generators was explanted
for normal ‘end of life’ within <7 years, 20.5% <5 years,
and 6.6% <3 years. These percentages increased over time
(Tab. 2).
Dual chamber systems were significantly more often ex-
planted for normal ‘end of life’ <5 years and <7 years
and technical reasons than single chamber systems (Tab. 3).
Overall, dual chamber systems were significantly more of-
ten explanted than single chamber systems (p  0.001;
Tab. 3).
Sensitivity analysis
A total of 258 participants of the Rotterdam Study were
found in the SPRN database. During the study period, 148
(57.4%) died. Of these deaths, 60 (40.5%) were also regis-
tered in SPRN. We consider 92% of these registrations to
be accurate (within 3 months from the registered date of
death in the Rotterdam Study). Age at death and implanted
pacemaker type did not statistically significantly differ be-
tween the group of patients registered as deceased and the
group of patients not registered as deceased in SPRN (p =
0.56 and p = 0.90, respectively).
Discussion
Our results show that 22% of pacemaker generators were
replaced or removed at least once between 1984 and 2008.
Approximately one in five pacemaker generators were ex-
planted due to technical failures or complications during
20 years of follow-up. Complication and failure rates for
pacemaker generators did not improve during at least the
first 15 years of the registry. Furthermore, we found that ex-
plantation of pacemaker generators for normal ‘end of life’
occurred at a decreasing follow-up time. The explantation
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Table 3 Comparison of specific replacement or explantation reasons between first pacemakers with NASPE codes VVI/VVIR and DDD/DDDR
in the nationwide CPPR-SPRN database, the Netherlands 1984–2007
VVI/VVIR DDD/DDDR p
n % n %
Number of first implantations of this pacemaker typea 47,945 49.5 38,060 39.3 –
Number of explantations of first pacemaker of this type 4391 9.2 5861 15.4 <0.001
Reason for explantation
Recall 141 3.2 209 3.6 0.328
Complication 226 5.1 350 6.0 0.073
Failure 161 3.7 154 2.6 0.003
Premature ‘end of life’ 123 2.8 164 2.8 0.993
Normal ‘end of life’
<7 years 1302 29.7 2716 46.3 <0.001
<5 years 273 6.2 690 11.8 <0.001
<3 years 53 1.2 46 0.8 0.408
NASPE North American Society of Pacing and Electrophysiology
a% compared to all first pacemaker implantations between 01.01.1984 and 01.01.2006, n = 96,900
rate found in the Danish Pacemaker Registry, which covers
the same period, compares to ours [15].
‘Normal service time’ of pacemaker generators in-
cludes the lifespan of the pacemaker generator in terms
of longevity of the battery and of the electronic compo-
nents. Time intervals between pacemaker implantation and
removal vary from a mean of 6.8 years for dual chamber
devices and 9.7 years for single chamber devices in one
study [16] and 7.3 years found in studies on several types
and brands of devices [13, 17]. Kindermann et al. found
a median time interval to battery depletion of 8.2 years [18].
However, cohort size, study duration, number of participat-
ing hospitals and number and type of different pacemakers
differed between these studies and differed compared with
ours.
More ancillary functions and operational algorithms than
standard pacing, sensing and communicating with the pro-
grammer, require more battery capacity and may thus affect
service time. This may cause newer models to offer shorter
service time than expected [17, 19]. Hauser et al. restricted
service time to the battery life time ending with the ap-
pearance of the elective replacement indicator, considering
a longevity of >3 years after implant as a minimal require-
ment [13]. They found that the average pulse generator
was implanted for 7.3 years (SD 3.1). The almost twofold
increase of the most frequently registered reason for pace-
maker generator replacement in our study – normal ‘end of
life’ – suggests that battery longevity did not improve dur-
ing at least the first 15 years of the study. This underscores
the need for longer service time of pacemaker generators
by new battery technology that permits pacing for at least
10 years. A longer ‘normal service time’ of pacemaker gen-
erators would be more than welcome because replacement
of pacemakers exposes patients to the risk of device infec-
tion.
Nearly one in five pacemaker generators was explanted
following a complication or failure in our study. A review
of reports submitted to the FDA and analysis of device reg-
istries published in literature show that pacemaker genera-
tor failures included acute or premature battery depletion,
connector malfunctions, electrical problems such as short
circuit, inappropriate high-current drains, or hermetic seal
abnormalities. Such complications sometimes cause major
clinical events [5, 6, 13]. Similar technical failures also
emerged in our registry: premature ‘end of life’, electrode
problems, recalls and device failures accounted for more
than 9% of the replacements of pacemaker generators in
our study. Furthermore, the percentage of explantations fol-
lowing a recall increased over time in parallel with medical
device regulation and post-marketing surveillance. Never-
theless, studies have shown that, despite increasing com-
plexity of the components of pacemaker generators over the
past decades, the overall replacement rate for technical fail-
ures dropped [5, 6]. However, technical defects may remain
unnoticed despite regular follow-up, as a previous study
implies [20]. This post-mortem study of pacemaker gener-
ators demonstrated that in 3.8% of patients, deceased after
an average of 4 years of pacing, a life-threatening technical
failure was present and in 3.0% a potentially life-threaten-
ing technical failure that may have caused their death [20].
The sensitivity analysis on the Rotterdam Study sub cohort
showed that 50% of the patients died within 3 years after
implantation of the last registered pacemaker. We cannot
rule out that a proportion of these patients died following
pacemaker malfunction.
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Limitations
In nearly 20% of the pacemaker generator replacements,
the reason and time for replacement or removal remained
unknown. Missing data could be ascribed to the voluntary
participation in the registration; some hospitals (<5%) did
not register data or did not register during the entire study
period. Data were provided by each participating hospital
individually. This may have led to differences in interpreta-
tion of the requested information. Relevant variables such
as information on comorbidity, medication use, and cardiac
function were not recorded at all. This precluded us from
adjusting for potential clinical confounders. Furthermore,
the registry did not include information on pacemaker set-
ting, pacing threshold and lead impedance. These factors
are known to influence battery longevity [17, 18].
Finally, detailed information on the proportion of pa-
tients that may have been lost to follow-up is unknown.
Information on date of death was voluntarily registered and
in 10% of the reported deaths no date of death was pro-
vided. Sensitivity analysis showed that approximately 60%
of the deaths could be missing.
Conclusions
A substantial proportion of pacemaker generators is ex-
planted before its expected service time, with one in five
generators being replaced due to technical failures, infec-
tions or complications. Furthermore, the time interval be-
tween pacemaker implantation and explantation due to nor-
mal ‘end of life’ decreased. Our observations underscore
the need to program only the pacemaker generator features
that have proven clinical benefit to avoid reductions of the
service time of the device. The results of our study indicate
that a continued highly detailed registry to identify risk fac-
tors for premature replacement is needed to maximise the
service time of pacemakers.
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